In Vitro and In Vivo Metabolism of a Novel Antimitochondrial Cancer Metabolism Agent, CPI-613, in Rat and Human
Sign Up to like & getrecommendations! Published in 2022 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.121.000726
Abstract: CPI-613, an inhibitor of pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (KGDH) enzymes, is currently in development for the treatment of pancreatic cancer, acute myeloid leukemia, and other cancers. CPI-613 is an analog of lipoic acid,… read more here.
Keywords: metabolism; oxidation; rat human; cpi 613 ... See more keywords
Abstract 527: Targeting citric acid cycle anaplerosis reverses the immunosuppressive phenotype of CD11b+Gr1+ myeloid cells in ovarian cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-527
Abstract: Immunosuppressive myeloid cells (CD11b+Gr1+) are a major constituent of the epithelial ovarian cancer (EOC) microenvironment that confer immunosuppression and promote tumor growth. We recently showed that the EOC microenvironment can induce metabolic reprogramming inCD11b+Gr1+ cells… read more here.
Keywords: cpi 613; cd11b gr1; ovarian cancer; myeloid cells ... See more keywords
Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.2626.2626
Abstract: Background:CPI-613 is a first in class agent that inhibits pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase. We have previously shown CPI-613 inhibits mitochondrial respiration, causes phosphorylation of PDH, activation of adenosine monophosphate activated kinase in acute… read more here.
Keywords: relapsed refractory; response; high dose; cpi 613 ... See more keywords
GA CPI 613: A single arm, open-label phase I study of CPI-613 in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.tps459
Abstract: TPS459 Background: Pancreatic cancer is the third leading cause of cancer death in the USA. The most effective treatments for first-line metastatic pancreatic cancer are FOLFIRINOX and gemcitabine plus nab-paclitaxel, which provide a median overall… read more here.
Keywords: cpi 613; cancer; study; nab paclitaxel ... See more keywords
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2023.41.4_suppl.tps760
Abstract: TPS760 Background: Local tumor progression is a cause of significant mortality and morbidity in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). Effective approaches to achieve durable local control are urgently needed. Metabolic reprogramming and enhanced… read more here.
Keywords: gem; phase; cpi 613; combination ... See more keywords
Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0266601
Abstract: Pancreatic cancer is the fourth leading cause of cancer death, with a 5-year survival rate of 10%. A stagnant high mortality rate over the last decades highlights the need for innovative therapeutic approaches. Pancreatic tumors… read more here.
Keywords: metabolism; pancreatic cancer; cpi 613; targeting pancreatic ... See more keywords
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Sign Up to like & getrecommendations! Published in 2019 at "Cancers"
DOI: 10.3390/cancers11111678
Abstract: One of the most significant therapeutic challenges in the treatment of ovarian cancer is the development of recurrent platinum-resistant disease. Cancer stem cells (CSCs) are postulated to contribute to recurrent and platinum-resistant ovarian cancer (OvCa).… read more here.
Keywords: cancer stem; inhibitor; treatment; ovarian cancer ... See more keywords
Development and validation of an LC-MS/MS method for determination of a novel anticancer agent (CPI-613) in human plasma.
Sign Up to like & getrecommendations! Published in 2022 at "Bioanalysis"
DOI: 10.4155/bio-2021-0270
Abstract: Background: This article describes the development and validation of a bioanalytical assay to quantify CPI-613 and its major metabolites, CPI-2850 and CPI-1810, in human plasma matrix using LC-MS/MS. Methodology: Sample extraction procedure following protein precipitation… read more here.
Keywords: development validation; cpi 613; human plasma; cpi ... See more keywords